News

To combat rising maternal mortality, researchers at Saint Luke's Mid America Heart Institute and UMKC are leading a first of its kind study to create better care for moms with heart conditions during pregnancy.

Alexis Ellington has a renewed outlook on life after being the first Saint Luke's patient to receive a new cancer treatment called Bispecific T-cell Engagers therapy, or BiTE.

The four-year observational study will research U.S. pregnant people with cardiovascular disease to better understand and combat maternal mortality and morbidity.

We are talking about lung cancer and how precision oncology helps patients diagnosed with the disease with treatment.

In the past, many women born with a heart condition were told they would not be able to birth children safely.

Over the years, they have done everything together: graduated high school, tied the knot, bought their first home, and raised a family. For all they have shared, they never dreamed of sharing a cancer diagnosis.

What began as a middle-of-the-night trip to the bathroom turned into a nightmare—and then a miracle—for 83-year-old Chillicothe resident Shirley Eskew. After getting out of bed, Shirley slipped and fell. “I just hit the concrete hard,” she remembers. Things got blurry after that, but she did manage to call for help and get to the emergency room at Hedrick Medical Center.